Puma Biotechnology(US:PBYI)2020-08-07 21:16NERLYNX Revenue and Sales - Net NERLYNX revenue for Q2 2020 was approximately $48.8 million[9] - Approximately 3,700 commercial bottles of NERLYNX were sold in Q2 2020[13] NERLYNX Dosing Trends - Approximately 31% of patients in Q2 2020 started NERLYNX at a reduced dose[17] Rest of World Partnerships - Regulatory and Launch Milestones - Australia/SE Asia: Approved in Australia (March 2019), Singapore (December 2019), Brunei, Malaysia, and New Zealand (Q2/Q3 2020)[22] - Israel: Launched in Q1 2020[22] - Canada: Approved in July 2019[22] - Greater China: Approved in Hong Kong (November 2019), China (April 2020), and Taiwan (August 2020)[22] - Latin America: Argentina-Launched (Q1 2020), Approved in Chile (Q2 2020), Ecuador (2H 2020), Brazil, Colombia, Mexico, Peru (2021)[22] - Europe Middle East North and West Africa South Africa Turkey: Germany-Launched (Q4 2019), United Kingdom-Launched (Q4 2019), Austria-Launched (Q4 2019), Sweden Launched (Q1 2020), Approved in Switzerland (Q1 2020), Rest of Territory (2020-2023)[22] - South Korea: NDA Filing expected by the end of 2020[22]